Fig. 4: HCMV-infected CD14⁺ monocytes are targets for HCMV-specific T cells upon VUN100bv treatment.

a Counting of IE-positive CD14⁺ monocytes before co-culture with CD4/CD8⁺ T cells or T-cell-depleted PBMCs. CD14⁺ monocytes were treated with a non-targeting nanobody (NT Nb), VUN100bv for 6 days post infection or pre-treated with 20 ng/ml PMA before infection. b Counting of IE-positive CD14⁺ monocytes after co-culture of T-cell-depleted PBMCs (depleted PBMC) or T cells (CD4/CD8) and differentiation of CD14⁺ monocytes to mature dendritic cells. c Counting of IE-positive CD14⁺ monocytes before co-culture with CD4/CD8⁺ T cells or T-cell-depleted PBMCs. Six days post infection, CD14⁺ monocytes were treated with NT Nb, VUN100bv, or 20 ng/ml PMA for 1 day. d Counting of IE-positive CD14⁺ monocytes after co-culture of T-cell-depleted PBMCs (depleted PBMC) or T cells (CD4/CD8) and differentiation of CD14⁺ monocytes to mature dendritic cells. Representative figures, showing technical replicates, from two biological replicates are shown. All data are plotted as mean ± S.D. For all figures, statistical analyses were performed using unpaired two-tailed t test. ns, p > 0.05. Source data are provided as a Source Data file.